3 Blue Chip Stocks That Have Soared 380% (and Higher) Over the Past 5 Years

Nvidia, Oracle, and Eli Lilly have demonstrated remarkable growth, delivering over 380% returns in the past five years, illustrating how established companies can achieve significant gains by leveraging major market trends. Nvidia's 1,290% surge is attributed to its dominance in AI chips, reaching a $4.57 trillion market cap with $87 billion in TTM earnings. Oracle's 381% increase stems from its cloud infrastructure and AI database advancements, while Eli Lilly's 462% growth is driven by its successful GLP-1 weight loss and diabetes drugs, making it the cheapest on a forward P/E basis at 24. These cases highlight the potential for robust returns from fundamentally strong businesses capitalizing on technological and pharmaceutical innovation.

Analysis

Nvidia (NVDA), Oracle (ORCL), and Eli Lilly (LLY) have delivered exceptional multi-year returns by leveraging dominant positions within secular growth trends, primarily artificial intelligence and novel pharmaceuticals. Nvidia's 1,290% five-year rally is underpinned by its leadership in the AI chip market, which has propelled its trailing-twelve-month earnings to nearly $87 billion from under $5 billion a few years ago. Despite its $4.57 trillion market capitalization, its forward price-to-earnings (P/E) multiple of 42 is presented as reasonable given this explosive earnings growth. Oracle, with a 381% five-year return, has benefited from the AI boom through its cloud infrastructure and upcoming 'Oracle AI Database', nearly doubling its TTM earnings to $12.4 billion over three years and trading at a similar 42 forward P/E. Separately, Eli Lilly's 462% gain is driven by its GLP-1 drugs, Zepbound and Mounjaro, which have doubled its bottom line to $13.8 billion TTM. With a forward P/E of 24, it is positioned as the most attractively valued growth asset among the three, highlighting how both tech and biopharma innovation are creating significant value in established, large-cap companies.

Key Decisions for Investors

• Investors should assess exposure to secular growth themes like AI and biopharma through fundamentally strong large-cap names, as these companies demonstrate a capacity for substantial, earnings-backed returns.
• For relative value, consider that while Nvidia and Oracle offer direct AI exposure at a high premium (42 forward P/E), Eli Lilly's combination of strong GLP-1 driven growth and a lower forward P/E of 24 may present a more compelling valuation for growth-focused portfolios.
• Monitor specific catalysts that underpin these valuations, including Nvidia's ability to sustain its earnings trajectory, the market adoption of Oracle's AI Database, and the continued market penetration and pipeline development for Eli Lilly's GLP-1 franchise.